.Nature Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of clients with HER2+ sophisticated bosom cancer cells and also active or steady human brain metastases presented consistent intracranial task and also wide spread efficiency of T-DXd.